Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib

Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia

(2011) Tomasz Rzymski et al.   CELL CYCLE

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

(2011) E. C. Lee et al.   CLINICAL CANCER RESEARCH

In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

(2011) Dharminder Chauhan et al.   CLINICAL CANCER RESEARCH

The IRE1α–XBP1 pathway is essential for osteoblast differentiation through promoting transcription of Osterix

(2011) Takahide Tohmonda et al.   EMBO REPORTS

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

(2011) Maurizio Zangari et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma

(2011) Masahiro Abe   INTERNATIONAL JOURNAL OF HEMATOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Endoplasmic Reticulum Stress Response Mediated by the PERK-eIF2α-ATF4 Pathway Is Involved in Osteoblast Differentiation Induced by BMP2

(2010) Atsushi Saito et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

(2010) Andrew D Chantry et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Osteoblastogenesis and tumor growth in myeloma

(2010) Shmuel Yaccoby   LEUKEMIA & LYMPHOMA

TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth

(2010) Kyoko Takeuchi et al.   PLoS One

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bortezomib induces osteoblast differentiation via Wnt-independent activation of  -catenin/TCF signaling

(2009) Y.-W. Qiang et al.   BLOOD

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-  converting enzyme (TACE)

(2009) M. Hiasa et al.   BLOOD

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation

(2009) Tomohiko Murakami et al.   NATURE CELL BIOLOGY

Critical Role of Activating Transcription Factor 4 in the Anabolic Actions of Parathyroid Hormone in Bone

(2009) Shibing Yu et al.   PLoS One

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Transcription factors controlling osteoblastogenesis

(2008) Pierre J. Marie   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

(2008) P. Moreau et al.   HAEMATOLOGICA

Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

(2008) Deborah J Heath et al.   JOURNAL OF BONE AND MINERAL RESEARCH

CCAAT/Enhancer-binding Protein β Promotes Osteoblast Differentiation by Enhancing Runx2 Activity with ATF4

(2008) Hiroyuki Tominaga et al.   MOLECULAR BIOLOGY OF THE CELL

From endoplasmic-reticulum stress to the inflammatory response

(2008) Kezhong Zhang et al.   NATURE